Barrington Research Reaffirms “Outperform” Rating for Option Care Health (NASDAQ:OPCH)

Barrington Research reaffirmed their outperform rating on shares of Option Care Health (NASDAQ:OPCH) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $38.00 price objective on the stock. Barrington Research also issued estimates for Option Care Health’s FY2024 earnings at $1.15 EPS, Q1 2025 earnings at $0.30 EPS, Q4 2025 earnings at $0.37 EPS, FY2025 earnings at $1.35 EPS and FY2026 earnings at $1.55 EPS.

Separately, Jefferies Financial Group upped their target price on shares of Option Care Health from $36.00 to $38.00 and gave the stock a buy rating in a report on Monday, March 4th.

Option Care Health Stock Up 1.1 %

OPCH opened at $29.61 on Wednesday. The company has a quick ratio of 1.33, a current ratio of 1.77 and a debt-to-equity ratio of 0.74. The stock has a market cap of $5.15 billion, a price-to-earnings ratio of 19.48, a PEG ratio of 1.43 and a beta of 1.22. Option Care Health has a twelve month low of $24.23 and a twelve month high of $35.74. The company’s 50-day moving average price is $31.96 and its two-hundred day moving average price is $31.48.

Option Care Health (NASDAQ:OPCH) last released its earnings results on Tuesday, April 23rd. The company reported $0.26 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $1.15 billion for the quarter, compared to analysts’ expectations of $1.10 billion. Option Care Health had a net margin of 6.15% and a return on equity of 18.92%. The company’s quarterly revenue was up 12.8% on a year-over-year basis. During the same period in the previous year, the company earned $0.21 earnings per share. As a group, equities analysts expect that Option Care Health will post 1.18 earnings per share for the current year.

Insider Transactions at Option Care Health

In related news, Director Harry M. Jansen Kraemer, Jr. bought 35,000 shares of the business’s stock in a transaction dated Monday, February 26th. The shares were purchased at an average price of $31.55 per share, with a total value of $1,104,250.00. Following the purchase, the director now owns 269,528 shares of the company’s stock, valued at approximately $8,503,608.40. The acquisition was disclosed in a document filed with the SEC, which is available through the SEC website. Corporate insiders own 0.64% of the company’s stock.

Institutional Investors Weigh In On Option Care Health

A number of large investors have recently modified their holdings of OPCH. Vontobel Holding Ltd. boosted its stake in shares of Option Care Health by 2.9% during the 3rd quarter. Vontobel Holding Ltd. now owns 13,168 shares of the company’s stock valued at $426,000 after purchasing an additional 374 shares in the last quarter. IFP Advisors Inc boosted its stake in Option Care Health by 20,350.0% during the third quarter. IFP Advisors Inc now owns 2,454 shares of the company’s stock worth $79,000 after acquiring an additional 2,442 shares in the last quarter. SG Americas Securities LLC boosted its stake in Option Care Health by 1,638.4% during the third quarter. SG Americas Securities LLC now owns 84,729 shares of the company’s stock worth $2,741,000 after acquiring an additional 79,855 shares in the last quarter. State of Alaska Department of Revenue boosted its stake in Option Care Health by 4.3% during the third quarter. State of Alaska Department of Revenue now owns 21,376 shares of the company’s stock worth $691,000 after acquiring an additional 880 shares in the last quarter. Finally, Avior Wealth Management LLC boosted its stake in Option Care Health by 30.5% during the third quarter. Avior Wealth Management LLC now owns 15,706 shares of the company’s stock worth $508,000 after acquiring an additional 3,670 shares in the last quarter. Institutional investors own 98.05% of the company’s stock.

About Option Care Health

Option Care Health, Inc offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders.